<DOC>
	<DOC>NCT00733902</DOC>
	<brief_summary>Test the efficacy and safety of 3 doses in Osteoarthritis of the knee in patients.</brief_summary>
	<brief_title>Tanezumab in Osteoarthritis of the Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<criteria>Osteoarthritis of the knee according to ACR criteria with a KellgrenLawrence xray grade of 2. Unwilling or unable to take nonopiate pain medications, for whom nonopiate pain medications have not provided adequate pain relief or are candidates for knee injections arthroplasty or replace surgery. Pain level and function levels as required by the protocol at Screening and Baseline. Willing to discontinue pain medications (acetaminophen will be permitted up to a certain level) before and during the study. Must agree to the contraceptive requirements of the protocol if applicable. Must agree to the treatment plan, scheduled visits, and procedures of the protocol. Pregnancy or intent to become pregnant during the study BMI greater than 39 other severe pain, significant cardiac, neurological or psychological conditions, or above the protocol limits for laboratory and blood pressure results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>monoclonal antibody</keyword>
	<keyword>RN624</keyword>
	<keyword>PF-04383119</keyword>
	<keyword>nerve growth factor</keyword>
	<keyword>anti-nerve growth factor</keyword>
	<keyword>OA</keyword>
	<keyword>pain</keyword>
</DOC>